Product Description
BSI-001 is an anti-HER2 humanized monoclonal antibody. BSI-001 binds distinct epitope with Herceptin and Perjeta and significantly improves the in vivo efficacy of Herceptin, it also shows 2x internalization vs Herceptin and Perjeta and significantly promotes the internalization of the HER2/Herceptin complex. HER2 promotes the growth of cancer cells and is overexpressed in breast cancer and gastric cancer patients. In Jul 2022, Biosion licensed China rights of BSI-001 to ANKEBIO for further development and commercialization. (Sourced from: https://www.biosion.com/pipeline)
Mechanisms of Action: ERBB2 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biosion
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|